- Oops!Something went wrong.Please try again later.
4D pharma plc (NASDAQ: LBPS) has completed its target enrollment of 30 patients for Part A of its Phase 1/2 trial of MRx-4DP0004 in patients with partly controlled asthma.
Following the completion of enrollment of Part A, the company expects to announce topline results from these patients in the second half of 2021.
Citing higher vaccination rates, the company also voluntarily discontinued the enrollment in the Phase 2 study of MRx-4DP0004 to treat hospitalized patients with COVID-19 in the U.K. to focus on its core pipeline candidates.
MRx-4DP0004 is an oral, immunomodulatory, single strain LBP. 4D pharma has demonstrated MRx-4DP0004's ability to reduce airway inflammation in a pre-clinical model of severe asthma.
It is achieved through a concurrent reduction in both neutrophilic and eosinophilic infiltration and inflammation.
Price Action: LBPS shares are down 1.3% at $10.53 during the market session on the last check Friday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.